Komen Scholar Spotlight

Ian E. Krop, M.D., Ph.D., is an Associate Professor of Medicine at Harvard Medical School. He is also the Chief of Breast Medical Oncology and Director of Clinical Research for the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute. Dr. Krop is a clinical translational medical oncologist whose primary research focuses on understanding and overcoming mechanisms of resistance to HER2-directed therapies. Dr. Krop played a major role in developing T-DM1 (KADCYLA® or ado-trastuzumab emtansine), a new therapy for HER2-positive breast cancers, including metastatic breast cancer. Dr. Krop is currently leading several clinical trials exploring combinations of novel targeted therapies designed to overcome resistance to HER2-directed agents. Dr. Krop’s Komen-funded research supports a project that seeks to understand how breast tumors and metastatic tumors from breast cancer patients become resistant to HER2-targeted therapies.